


CAR T-Cell Therapy Platform


In recent years, cancer treatment has shifted significantly with the rise of immunotherapies like CAR T-cell therapy, which directly targets cancer cells using the body's immune system, showing promise in clinical trials for various cancers. Reaction Biology leads in immuno-oncology, offering tailored preclinical services, including a robust CAR T-cell therapy platform. With expert guidance and comprehensive testing services, we aim to accelerate therapy development and make impactful contributions to cancer immunotherapy.




Comprehensive efficacy and PK solution for CD19 CAR T-cells

Gain critical data on potency and functionality and optimize your therapeutic design through comprehensive testing across a range of *in vitro* and *in vivo* models


Case I: Assess donor-to-donor variability of CD19 CAR T-cells in B cell leukemia model



Case II: Measure *in vitro* cytotoxicity of CD19 CAR T-cells in NALM-6 and MOLM-13 cell lines




Case III: Evaluate the activation and memory status of CD19 CAR T-cells via flow cytometry



Test the effect of your CAR T-cells in solid tumors

Leverage our cutting-edge *in vitro* and *in vivo* models and assays to evaluate the efficacy of CAR T-cells based on their ability to infiltrate and target solid tumor

Case IV: Test anti-tumor activity of CAR T-cells in NSG mice engrafted with a subcutaneous THP-1 xenograft tumor model



Ignite the next wave of CAR T breakthroughs. Let's discover together.



Reaction Biology Corp.

- 1 Great Valley Parkway, Suite 2 Malvern, 19355, PA, USA
- sales@reactionbiology.com
- +1.610.722.0247

v1.1 March 2024

REACTION
BIOLOGY